AUR vs. RXRX

Last updated Apr 2, 2026

Compare and contrast key facts about Aurora Innovation, Inc. (AUR) and Recursion Pharmaceuticals, Inc. (RXRX).

Performance

AUR vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Aurora Innovation, Inc. (AUR) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

AUR vs. RXRX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
AUR Aurora Innovation, Inc.	8.85%	-39.05%	44.16%	261.16%	-89.25%	12.60%
RXRX Recursion Pharmaceuticals, Inc.	-25.18%	-39.50%	-31.44%	27.89%	-54.99%	-25.65%

Fundamentals

Market Cap AUR : $8.09B RXRX : $1.61B
EPS AUR : -$0.44 RXRX : -$1.39
PS Ratio AUR : 2.61K RXRX : 19.03
PB Ratio AUR : 3.78 RXRX : 1.43
Total Revenue (TTM) AUR : $3.00M RXRX : $74.56M
Gross Profit (TTM) AUR : -$14.00M RXRX : $3.73M
EBITDA (TTM) AUR : -$843.00M RXRX : -$579.69M

Returns By Period

In the year-to-date period, AUR achieves a 8.85% return, which is significantly higher than RXRX's -25.18% return.

AUR

• 1D: 1.46%
• 1M: -12.00%
• YTD: 8.85%
• 6M: -19.77%
• 1Y: -37.89%
• 3Y*: 44.34%
• 5Y*: —
• 10Y*: —

RXRX

• 1D: -0.33%
• 1M: -15.70%
• YTD: -25.18%
• 6M: -40.00%
• 1Y: -39.94%
• 3Y*: -22.87%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

AUR vs. RXRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AUR

AUR Risk / Return Rank: 18
AUR Sharpe Ratio Rank: 15
AUR Sortino Ratio Rank: 16
AUR Omega Ratio Rank: 18
AUR Calmar Ratio Rank: 16
AUR Martin Ratio Rank: 22

RXRX

RXRX Risk / Return Rank: 18
RXRX Sharpe Ratio Rank: 19
RXRX Sortino Ratio Rank: 22
RXRX Omega Ratio Rank: 23
RXRX Calmar Ratio Rank: 15
RXRX Martin Ratio Rank: 11

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AUR vs. RXRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Aurora Innovation, Inc. (AUR) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	AUR	RXRX	Difference
Sharpe ratio Return per unit of total volatility	-0.60	-0.48	-0.12
Sortino ratio Return per unit of downside risk	-0.64	-0.32	-0.32
Omega ratio Gain probability vs. loss probability	0.93	0.97	-0.03
Calmar ratio Return relative to maximum drawdown	-0.70	-0.72	+0.02
Martin ratio Return relative to average drawdown	-1.03	-1.43	+0.40
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

AUR vs. RXRX - Sharpe Ratio Comparison

The current AUR Sharpe Ratio is -0.60, which is comparable to the RXRX Sharpe Ratio of -0.48. The chart below compares the historical Sharpe Ratios of AUR and RXRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	AUR	RXRX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.60	-0.48	-0.12
Sharpe Ratio (All Time) Calculated using the full available price history	-0.18	-0.40	+0.22

Correlation

The correlation between AUR and RXRX is 0.43, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

AUR vs. RXRX - Dividend Comparison

Neither AUR nor RXRX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

AUR vs. RXRX - Drawdown Comparison

The maximum AUR drawdown since its inception was -93.34%, roughly equal to the maximum RXRX drawdown of -93.13%. Use the drawdown chart below to compare losses from any high point for AUR and RXRX.

Drawdown Indicators

	AUR	RXRX	Difference
Max Drawdown Largest peak-to-trough decline	-93.34%	-93.13%	-0.21%
Max Drawdown (1Y) Largest decline over 1 year	-53.69%	-58.17%	+4.48%
Current Drawdown Current decline from peak	-75.57%	-92.60%	+17.03%
Average Drawdown Average peak-to-trough decline	-67.57%	-74.78%	+7.21%
Ulcer Index Depth and duration of drawdowns from previous peaks	36.61%	29.48%	+7.13%

Volatility

AUR vs. RXRX - Volatility Comparison

Aurora Innovation, Inc. (AUR) has a higher volatility of 16.39% compared to Recursion Pharmaceuticals, Inc. (RXRX) at 14.66%. This indicates that AUR's price experiences larger fluctuations and is considered to be riskier than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	AUR	RXRX	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.39%	14.66%	+1.73%
Volatility (6M) Calculated over the trailing 6-month period	42.02%	54.53%	-12.51%
Volatility (1Y) Calculated over the trailing 1-year period	63.85%	83.97%	-20.12%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	90.05%	94.52%	-4.47%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	90.05%	94.52%	-4.47%

Financials